These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

192 related items for PubMed ID: 37414267

  • 21. EBV-PTLD in a patient after haploidentical stem-cell transplantation with post-transplant cyclophosphamide.
    Terao T, Tsushima T, Fukumoto A, Kuzume A, Miura D, Narita K, Takeuchi M, Matsue K.
    Int J Hematol; 2021 Jul; 114(1):136-140. PubMed ID: 33675520
    [Abstract] [Full Text] [Related]

  • 22.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 23. Impact of prophylaxis with rituximab on EBV-related complications after allogeneic hematopoietic cell transplantation in children.
    Marjańska A, Pogorzała M, Dziedzic M, Czyżewski K, Richert-Przygońska M, Dębski R, Bogiel T, Styczyński J.
    Front Immunol; 2024 Jul; 15():1427637. PubMed ID: 39055711
    [Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26. Successful preemptive therapy with single-dose rituximab for Epstein-Barr virus infection to prevent post-transplant lymphoproliferative disease after pediatric hematopoietic stem cell transplantation.
    Kim BK, Kang HJ, Hong KT, An HY, Choi JY, Lee JS, Park SS, Shin HY.
    Transpl Infect Dis; 2019 Dec; 21(6):e13182. PubMed ID: 31556214
    [Abstract] [Full Text] [Related]

  • 27. Post-transplant lymphoproliferative disorder of the adrenal gland after allogeneic hematopoietic stem cell transplantation: report of two cases and literature review.
    Kasahara H, Mori T, Kato J, Koda Y, Kohashi S, Kikuchi T, Sakurai M, Yamane Y, Mikami S, Kameyama K, Takahashi Y, Okamoto S.
    Transpl Infect Dis; 2015 Dec; 17(6):909-14. PubMed ID: 26426682
    [Abstract] [Full Text] [Related]

  • 28. T-cell posttransplant lymphoproliferative disorders after allogeneic hematopoietic cell transplantation.
    Kuno M, Ito A, Maeshima AM, Taniguchi H, Tanaka T, Inamoto Y, Kurosawa S, Kim SW, Fukuda T.
    Int J Hematol; 2020 Aug; 112(2):193-199. PubMed ID: 32472530
    [Abstract] [Full Text] [Related]

  • 29. Successful management of EBV-PTLD in allogeneic bone marrow transplant recipient by virological-immunological monitoring of EBV infection, prompt diagnosis and early treatment.
    Chiereghin A, Bertuzzi C, Piccirilli G, Gabrielli L, Squarzoni D, Turello G, Ferioli M, Sessa M, Bonifazi F, Zanoni L, Sabattini E, Lazzarotto T.
    Transpl Immunol; 2016 Feb; 34():60-4. PubMed ID: 26687013
    [Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31. Epstein Barr virus-directed T-cell therapy for refractory EBV-PTLD in a toddler post Orthotopic heart transplantation.
    Work E, Gupta D, Slayton WB, Rees J, Coppola JA, Seifert R, Bleiweis MS, Jacobs JP, Peek G, Philip J, Brock A, Rivera JH, Sullivan K, Narasimhulu SS.
    Pediatr Transplant; 2024 Mar; 28(2):e14707. PubMed ID: 38419558
    [Abstract] [Full Text] [Related]

  • 32. Intrathecal therapy with rituximab in central nervous system involvement of post-transplant lymphoproliferative disorder.
    Czyzewski K, Styczynski J, Krenska A, Debski R, Zajac-Spychala O, Wachowiak J, Wysocki M.
    Leuk Lymphoma; 2013 Mar; 54(3):503-6. PubMed ID: 22873830
    [Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34. Epstein-Barr virus post-transplant lymphoproliferative disease (PTLD) after hematopoietic stem cell transplantation.
    Ru Y, Chen J, Wu D.
    Eur J Haematol; 2018 Sep; 101(3):283-290. PubMed ID: 29949208
    [Abstract] [Full Text] [Related]

  • 35. Expert Consensus on the Characteristics of Patients with Epstein-Barr Virus-Positive Post-Transplant Lymphoproliferative Disease (EBV+ PTLD) for Whom Standard-Dose Chemotherapy May be Inappropriate: A Modified Delphi Study.
    Chaganti S, Barlev A, Caillard S, Choquet S, Cwynarski K, Friedetzky A, González-Barca E, Sadetsky N, Schneeberger S, Thirumalai D, Zinzani PL, Trappe RU.
    Adv Ther; 2023 Mar; 40(3):1267-1281. PubMed ID: 36681739
    [Abstract] [Full Text] [Related]

  • 36. [Clinical Analysis of Post-Transplant Lymphoproliferative Disorder after Hematopoietic Stem Cell Transplantation in Severe Aplastic Anemia Patients].
    Yan HM, Zheng XL, Zhu L, Ding L, Han DM, Liu J, Xue M, Li S, Wang HX.
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2022 Aug; 30(4):1224-1229. PubMed ID: 35981389
    [Abstract] [Full Text] [Related]

  • 37. Outcome of treatment of Epstein-Barr virus-related post-transplant lymphoproliferative disorder in hematopoietic stem cell recipients: a comprehensive review of reported cases.
    Styczynski J, Einsele H, Gil L, Ljungman P.
    Transpl Infect Dis; 2009 Oct; 11(5):383-92. PubMed ID: 19558376
    [Abstract] [Full Text] [Related]

  • 38. EBV Reactivation and Disease in Allogeneic Hematopoietic Stem Cell Transplant (HSCT) Recipients and Its Impact on HSCT Outcomes.
    Law N, Logan C, Taplitz R.
    Viruses; 2024 Aug 14; 16(8):. PubMed ID: 39205268
    [Abstract] [Full Text] [Related]

  • 39. Epstein-Barr virus DNA load kinetics analysis in allogeneic hematopoietic stem cell transplant recipients: Is it of any clinical usefulness?
    Solano C, Mateo EM, Pérez A, Talaya A, Terol MJ, Albert E, Giménez E, Vinuesa V, Piñana JL, Boluda JCH, Navarro D.
    J Clin Virol; 2017 Dec 14; 97():26-32. PubMed ID: 29096390
    [Abstract] [Full Text] [Related]

  • 40. Long-term outcome of Epstein-Barr virus DNAemia and PTLD with the use of preemptive rituximab following allogeneic HSCT.
    Kinch A, Hallböök H, Arvidson J, Sällström K, Bondeson K, Pauksens K.
    Leuk Lymphoma; 2018 May 14; 59(5):1172-1179. PubMed ID: 28831836
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 10.